文献速递慢性肾脏病遗传性与小管间质肾病

营养性维生素D补充对慢性肾脏病患儿骨矿物质代谢标志物的影响

Effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

本研究纳入80例维生素D缺乏的CKD患儿,其中40例轻度至中度CKD来自ERGO随机试验,40例晚期CKD来自4C观察性研究,每组20例补充维生素D、20例匹配对照。补充中位8个月后,轻度至中度CKD患儿Klotho和sclerostin恢复正常,但晚期CKD患儿FGF23进一步升高,BAP在所有患者中均未变化。

要点

  • 轻度至中度CKD患儿补充维生素D后Klotho和sclerostin恢复正常。
  • 晚期CKD患儿补充维生素D后FGF23进一步升高。
  • BAP水平在所有患者中均未因补充维生素D而改变。

核心结论

  • 维生素D补充可使轻度至中度CKD患儿Klotho和sclerostin恢复正常,但在晚期CKD患儿中进一步升高FGF23。

研究设计与样本

  • 共纳入80例维生素D缺乏的CKD患儿:40例来自ERGO随机试验(eGFR 55 mL/min/1.73 m2),40例来自4C观察性研究(eGFR 24 mL/min/1.73 m2)。
  • 每项研究中20例开始补充维生素D,20例匹配患儿作为对照未补充。
  • 基线及中位8个月后测量指标,计算年龄和性别相关的标准差评分(SDS)。

主要发现

  • 补充前,ERGO患儿FGF23(中位0.31 SDS)和BAP(-0.10 SDS)正常,但Klotho和sclerostin降低(分别为-0.77和-1.04 SDS)。
  • 补充前,4C患儿FGF23(3.87 SDS)、BAP(0.78 SDS)和sclerostin(0.76 SDS)升高,但Klotho正常(-0.27 SDS)。
  • 补充维生素D后,4C患儿FGF23进一步升高,ERGO患儿无此变化。
  • 补充维生素D后,ERGO患儿Klotho和sclerostin恢复正常,4C患儿保持不变。
  • 所有患者BAP水平均未改变;总队列中,维生素D补充对Klotho的显著效应见于eGFR 40-70 mL/min/1.73 m2。

临床怎么用

  • 对于轻度至中度CKD的维生素D缺乏患儿,补充维生素D可能改善Klotho和sclerostin水平。
  • 对于晚期CKD患儿,补充维生素D需注意FGF23可能进一步升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We investigated the effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism, i.e. serum levels of fibroblast growth factor 23 (FGF23), Klotho, bone alkaline phosphatase (BAP) and sclerostin, in two cohorts with chronic kidney disease (CKD). METHODS: In all, 80 vitamin D-deficient children were selected: 40 with mild to moderate CKD from the ERGO study, a randomized trial of ergocalciferol supplementation [estimated glomerular filtration rate (eGFR) 55 mL/min/1.73 m2], and 40 with advanced CKD from the observational Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study (eGFR 24 mL/min/1.73 m2). In each study, vitamin D supplementation was started in 20 children and 20 matched children not receiving vitamin D served as controls. Measures were taken at baseline and after a median period of 8 months. Age- and gender-related standard deviation scores (SDSs) were calculated. RESULTS: Before vitamin D supplementation, children in the ERGO study had normal FGF23 (median 0.31 SDS) and BAP (-0.10 SDS) but decreased Klotho and sclerostin (-0.77 and -1.04 SDS, respectively), whereas 4C patients had increased FGF23 (3.87 SDS), BAP (0.78 SDS) and sclerostin (0.76 SDS) but normal Klotho (-0.27 SDS) levels. Vitamin D supplementation further increased FGF23 in 4C but not in ERGO patients. Serum Klotho and sclerostin normalized with vitamin D supplementation in ERGO but remained unchanged in 4C patients. BAP levels were unchanged in all patients. In the total cohort, significant effects of vitamin D supplementation were noted for Klotho at eGFR 40-70 mL/min/1.73 m2. CONCLUSIONS: Vitamin D supplementation normalized Klotho and sclerostin in children with mild to moderate CKD but further increased FGF23 in advanced CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Lerch C, Shroff R, Wan M, et al. Effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease. Nephrol Dial Transplant. 2018. PMID: 29481636. doi:10.1093/ndt/gfy012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。